Sigma binding site agents having the formula STR1 which are useful to inhibit sigma binding site-induced activity, pharmaceutical compositions including these agents, and methods of using these agents to inhibit sigma binding site-induced activity in mammals. Also disclosed are novel intermediates useful in preparing the presently invented agents.
A series of (aminoalkoxy)chromones has been prepared, members of which bind potently (16-100 nM) at the ? binding site and bind weakly (>1000 nm) at the dopamine D2 receptor and 33 other receptors, second messenger systems, and ion channels.At
Erickson, Ronald H.,Natalie, Kenneth J.,Bock, William,Lu, Zhijian,Farzin, Farzaneh,et al.
p. 1526 - 1535
(2007/10/02)
More Articles about upstream products of 139653-14-8